Want to see HK:8156 full AI Analyst Report?
8156 Stock Chart & Stats
HK$0.22
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.22
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.06 - HK$0.39
Previous CloseN/A
Volume194.40K
Average Volume (3M)157.92K
Market Cap
HK$101.39M
Enterprise ValueHK$229.85
Total Cash (Recent Filing)HK$12.88M
Total Debt (Recent Filing)HK$34.55M
Price to Earnings (P/E)21.6
Beta0.38
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding633,693,050
10 Day Avg. Volume46,340
30 Day Avg. Volume157,918
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)-2.33
Price to Sales (P/S)1.40
P/FCF Ratio-11.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained, very strong top-line expansion increases addressable market penetration and creates scale opportunities. Over 2-6 months this growth can underpin margin recovery and operational leverage if management converts revenue into improved unit economics and scalable customer acquisition.
Improving Free Cash FlowAn improving free cash flow trend signals progress toward self-funded operations and reduces dependency on external capital. If sustained, stronger FCF supports reinvestment, product development or deleveraging, which materially improves long-term financial flexibility and survival odds.
Software Application Industry ScalabilityOperating in a software application vertical offers structural advantages—low incremental costs per user and potential for high gross margins. A small headcount implies lower fixed cost base, enabling operating leverage as revenue scales and supporting durable margin improvement if product-market fit is sustained.
Bears Say
Negative ProfitabilityPersistently negative net profit and EBIT margins limit the company's ability to internally fund growth and signal underlying operating inefficiencies. Over months this hinders reinvestment, weakens investor confidence, and raises execution risk unless margins move sustainably into positive territory.
Negative Equity And High LeverageNegative shareholders' equity and significant leverage materially constrain strategic options: higher financing costs, impaired access to capital markets, and increased default risk. These structural balance-sheet weaknesses limit resilience to shocks and slow recovery even if operations improve.
Negative Operating Cash FlowNegative operating cash flow indicates core business activities are not generating sufficient cash, forcing reliance on financing or asset sales. Persisting over months, this creates liquidity pressure, curtails investment capacity, and magnifies refinancing risk during tightening credit conditions.
8156 FAQ
What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?
Sinopharm Tech Holdings Limited lowest stock price was HK$0.06 and its highest was HK$0.39 in the past 12 months.
What is Sinopharm Tech Holdings Limited’s market cap?
Sinopharm Tech Holdings Limited’s market cap is HK$101.39M.
When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?
Sinopharm Tech Holdings Limited’s upcoming earnings report date is Sep 25, 2026 which is in 40 days.
How were Sinopharm Tech Holdings Limited’s earnings last quarter?
Sinopharm Tech Holdings Limited released its earnings results on Feb 26, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sinopharm Tech Holdings Limited overvalued?
According to Wall Street analysts Sinopharm Tech Holdings Limited’s price is currently Overvalued.
Does Sinopharm Tech Holdings Limited pay dividends?
Sinopharm Tech Holdings Limited does not currently pay dividends.
What is Sinopharm Tech Holdings Limited’s EPS estimate?
Sinopharm Tech Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Tech Holdings Limited have?
Sinopharm Tech Holdings Limited has 633,693,050 shares outstanding.
What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?
Sinopharm Tech Holdings Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.273%.
Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?
Currently, no hedge funds are holding shares in HK:8156
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sinopharm Tech Holdings Limited
Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware and software systems for lottery services; develops and implements "Internet Plus" solutions for various industries including healthcare, government administration, property leasing, and public security; engages in the manufacturing and distribution of personal protective equipment; and offers additional services such as corporate management, supply chain optimization, data analytics, and online trading of goods. Founded in 1999 and headquartered in Sha Tin, Hong Kong, the company rebranded to Sinopharm Tech Holdings Limited in June 2019, having previously traded as China Vanguard You Champion Holdings Limited.
Technical Analysis
Aurum Pacific (China) Group Ltd.
―
YSB Inc.
―
Zhejiang Taimei Medical Technology Co Ltd Class H
―
Beijing Saimo Technology Co. Ltd. Class H
―
JST Group Corporation Limited
―